PHOENIX--(BUSINESS WIRE)--Creative Medical Technologies, Inc. (CMT) announced today filing of a patent covering regenerative technologies for the treatment of a subset of women suffering from sexual dysfunction associated with vascular abnormalities. The patent covers uses of various proteins obtained from regenerative cells, including stem cells, which are potentially useful in addressing sexual dysfunction in a subset of women who are unable to achieve sexual arousal due to insufficiencies of blood flow.
“Peer reviewed publications have previously shown that vaginal engorgement and clitoral erection depend on increased blood inflow. Atherosclerosis is associated with vaginal engorgement insufficiency and clitoral erectile insufficiency1,” said Thomas Ichim, Ph.D., board member of CMT and inventor of the patent application. “Through utilization of regenerative technologies to augment blood flow, we believe we have a series of potential therapeutic candidates that can address this unmet medical need.”
The principle of leveraging regenerative medicine in the form of stem cells to increase blood flow to atherosclerotic tissue was successfully demonstrated by members of the CMT team, who previously utilized cellular-based therapies to treat diseases associated with vascular deficiencies in animal models2 and pilot clinical trials3. CMT is applying these same principles, using different regenerative medicine approaches, to sexual dysfunction. In many cases, both male sexual dysfunction, in the form of erectile dysfunction, and female sexual dysfunction have an association with reduced blood flow to critical tissues.
CMT has previously patented4 and published data on the first patient treated5 using stem cell therapy for erectile dysfunction. The current patent is a continuation of existing research and expansion into a new market that is largely unaddressed by current approaches.
“According to a peer-reviewed publication authored by researchers at Cedars-Sinai Medical Center6, approximately 40% of women suffer from sexual dysfunction at some point in their lives7. We believe that addressing this unmet medical need using regenerative medicine has the potential to offer greater benefit with superior safety profile,” said Timothy Warbington, President and Chief Executive Officer of CMT.
Creative Medical Technologies, Inc. is a spinoff company from Creative Medical Health, Inc., which develops novel regenerative medicine and stem cell technologies in the areas of male and female sexual dysfunction and male infertility; cardiovascular disease (AngioStem Inc. another Creative Medical Health Inc. spinoff); treatment of insulin resistance related to Type 2 Diabetes; autoimmune diseases and disc degenerative disease.
| 1 | Park et al. Int J Impot Res. 1997 Mar;9(1):27-37. | |
| 2 | Murphy et al. J Transl Med. 2008 Aug 19;6:4 | |
| 3 | Bockeria et al. J Transl Med. 2013 Mar 5;11:56 | |
| 4 | ||
| 5 |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718667/pdf/1479-5876-11-139.pdf |
|
| 6 | Houman et al. Curr Urol Rep. 2016 Apr;17(4):28 | |
| 7 | Loumann et al. JAMA. 1999 Feb 10;281(6):537-44. |